This site is intended only for healthcare professionals resident in the Republic of Ireland
MADELINE (Mobile App Diary of Everyday Life and Experiences) was a prospective, non-interventional, multicenter longitudinal study of PROs in women receiving IBRANCE combination therapy for ABC/mBC.¹
MADELINE was one of the first studies to evaluate day-to-day impacts of ABC/mBC and treatment on patients, outside of clinical trials.¹
Patients received daily reminders to track their pain level, fatigue level and mood.¹
Safety endpoints included the incidence, severity and duration of neutropenia events and other AEs occurring during the study.¹
At each cycle, the relationship between all PROs and neutropenia was explored by comparing patients without neutropenia during the study (for the cycle-based PROs) and patients with neutropenia at the time point.¹
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023